Allergan Inc. Reaches New 12-Month High at $121.12 (AGN)
Allergan (NYSE:AGN)’s share price reached a new 52-week high during trading hours on Tuesday, AnalystRatings.NET reports. The company traded as high as $121.12 and last traded at $120.34, with a volume of 4,795,288 shares traded. The stock had previously closed at $114.42.
AGN has been the subject of a number of recent research reports. Analysts at Argus raised their price target on shares of Allergan from $110.00 to $125.00 in a research note to investors on Wednesday, January 8th. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Allergan from $103.00 to $122.00 in a research note to investors on Tuesday, January 7th. Finally, analysts at RBC Capital initiated coverage on shares of Allergan in a research note to investors on Tuesday, January 7th. They set an “outperform” rating and a $131.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $114.50.
Allergan has a one year low of $81.33 and a one year high of $116.45. The stock’s 50-day moving average is $104.0 and its 200-day moving average is $93.7. The company has a market cap of $35.903 billion and a price-to-earnings ratio of 34.68.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, October 29th. The company reported $1.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.20 by $0.03. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter last year, the company posted $1.06 earnings per share. Allergan’s revenue was up 13.3% compared to the same quarter last year. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.